US 8986670

I'll search for authoritative information on US patent 8986670, including any 2026 CAFC activity.

Let me check for any litigation/CAFC activity and pull the actual claim set.

Let me try to retrieve the granted claim text and check for any appellate/litigation activity once more.

US Patent 8,986,670 — Analyst Summary

⚠️ Search-scope caveats (read first)

• I ran targeted searches for US 8,986,670 specifically (not adjacent numbers) against patent databases and general web sources, and a dedicated search for Court of Appeals for the Federal Circuit 2026 dockets referencing this patent. The CAFC/2026 docket search returned no results. I have no authoritative evidence of any 2026 Federal Circuit appeal, PTAB/IPR proceeding, or district-court litigation involving US 8,986,670. I cannot confirm one exists, and I will not infer one.
• The full claim set is not reproduced in the authoritative source I retrieved (the granted-claims section was blank/omitted). The independent-claim overview below is reconstructed from the patent's own "Summary of the Invention" and detailed description. Treat the claim overview as substantively accurate but not verbatim. If you need exact claim wording for a validity/infringement purpose, pull the granted claims directly from USPTO PatentCenter or the issued patent PDF.

Bibliographic data

Abstract (verbatim)

"The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival."

Plain-language overview of the independent claims

Based on the Summary of the Invention, the patent's independent claims fall into treatment claims, cell-culture/biology claims, and a composition claim:

1. Treating a non-immune, non-infectious demyelinating peripheral neuropathy. Administer a therapeutically effective amount of polyclonal IgG to a mammal diagnosed with a demyelinating peripheral neuropathy, where the neuropathy is neither immune-mediated nor infection-mediated. The specification expressly contemplates that the neuropathy is not Guillain-Barré syndrome (GBS), CIDP, or multifocal motor neuropathy, and that it is non-idiopathic (cause known). Contemplated categories: trauma-induced, toxin-induced, inherited, and metabolic-disease-induced (e.g., diabetic) neuropathy. Plainly: use IVIG-type pooled IgG to help re-insulate damaged peripheral nerves whose damage came from physical injury, poison/drug exposure, genes, or diabetes — not from autoimmunity or infection.

2. Treating peripheral nerve trauma. Administer a therapeutically effective amount of polyclonal IgG to a mammal with peripheral nerve trauma (e.g., severed, crushed, compressed, or stretched nerves from accidents, combat, falls, sports, electric shock, hypothermia).

3. Treating toxin-induced peripheral neuropathy. Administer a therapeutically effective amount of polyclonal IgG to a mammal diagnosed with toxin/chemical-induced peripheral neuropathy, where the neuropathy is not infection-mediated (e.g., chemotherapy agents such as vincristine, cisplatin, paclitaxel, methotrexate; industrial solvents; heavy metals).

4. Promoting myelination. Contact a Schwann cell with an amount of polyclonal IgG sufficient to promote myelination of a peripheral nerve cell by that Schwann cell.

5. Promoting Schwann cell differentiation. Contact an immature Schwann cell with polyclonal IgG in an amount sufficient to drive its differentiation into a myelinating state.

6. Promoting myelin production. Contact a Schwann cell with an amount of polyclonal IgG sufficient to upregulate the MBP (myelin basic protein) gene.

7. Culturing nervous tissue. Culture mammalian nervous tissue containing axons by contacting it with effective amounts of Schwann cells and polyclonal IgG, such that MBP gene expression is upregulated.

8. Treating peripheral nerve injury by transplant. Transplant nerve cells to the injury site and contact them with a composition comprising Schwann cells + polyclonal IgG.

9. Pharmaceutical composition. A composition comprising a pharmaceutically acceptable carrier and an effective amount of polyclonal IgG for treating a non-idiopathic demyelinating peripheral neuropathy.

Dependent/embodiment features referenced in the summary and description include: route of administration (local IM/ID; systemic IV, SC, intranasal, oral, intra-arterial); co-administration with an anti-inflammatory agent (ACTH, corticosteroid, interferon, glatiramer acetate, NSAID); dosing (weekly/biweekly/monthly at ~0.05–5 g/kg, or ~0.5–2 g/kg); pooled human serum as IgG source; human or domesticated-animal subjects.

Technical basis (as stated in the specification)

• The inventors' discovery: exogenous polyclonal IgG directly promotes Schwann cell maturation, differentiation, and myelin gene expression — a mechanism independent of IVIG's classical immunomodulatory role used to explain its benefit in GBS/CIDP/MMN.
• Supporting experiments include BrdU and Ki-67 proliferation assays (Figs. 1–2), P0 and MBP gene expression in immature Schwann cells and in p57kip2-suppressed Schwann cells (Figs. 3–4), CD64 Fc-receptor expression (Fig. 5), process outgrowth/morphology (Figs. 6–8), and a DRG-neuron/Schwann cell myelinating co-culture (Fig. 9).
• Notably, the specification reports that monoclonal IgG1 controls (Synagis, Avastin, Herceptin) showed no significant effect on myelin gene expression, contrasting with pooled polyclonal IVIG.
• The specification hypothesizes CD64 (FcγRI)-dependent signaling (with Syk/PI3K inhibitor experiments and Fab/Fc digestion studies proposed) — i.e., a ligand–receptor model between IgG and Schwann cells.

Bottom line

US 8,986,670 is a Baxter-originated, now Takeda-held patent claiming use of polyclonal IgG (IVIG-type) to treat non-immune, non-infectious demyelinating peripheral neuropathies (trauma-, toxin-, inherited-, and diabetes-related), plus Schwann-cell/culture and composition claims — grounded in the finding that pooled IgG directly drives Schwann cell differentiation and MBP/myelin expression. It issued 2015-03-24 with a 2033 anticipated expiry and is part of a multi-patent continuation family. I found no 2026 CAFC docket activity for this patent, and I could not verify verbatim claim language from the authoritative source retrieved — please confirm exact claims via USPTO PatentCenter before relying on them for legal analysis.

Answer: No litigation found involving U.S. Patent No. 8,986,670

I searched for litigation involving U.S. Patent No. 8,986,670 (both as "8986670" and as "8,986,670"), including targeted searches aimed at litigation-tracking sources (Unified Patents litigation portal, PACER/CAFC-style dockets, and general web/legal-news sources). I found no record of any district court action, Federal Circuit appeal, PTAB proceeding, or other litigation involving this specific patent.

What the searches did and did not return

Searches that did return patent-litigation cases returned them for different patent numbers (e.g., Music Choice's patents 8,769,602 / 9,357,245; Bot M8's 8,112,670; Akamai's '667 patent). Per your instruction, I did not treat any of those as responsive — none is U.S. 8,986,670.

Important caveats (please read before relying on this)

1. This is a negative finding from limited searching, not a certified "no litigation" clearance. I was unable to directly query the Unified Patents litigation dashboard, PACER, or Docket Navigator; the searches were run through a general web-search interface, which does not exhaustively index sealed, recently filed, or non-electronic dockets.
2. The nature of the patent makes litigation less likely, but not impossible. U.S. 8,986,670 is a biologic/method-of-treatment patent (polyclonal IgG / IVIG for non-idiopathic demyelinating peripheral neuropathy). Its owner chain — Baxter Healthcare SA / Baxter International → Baxalta → Takeda Pharmaceutical Company Limited (current assignee per the record before me) — suggests it is a defensive portfolio asset rather than an assertion vehicle. No evidence of assertion was found either way.
3. Do not rely on any case number I might infer. I found no case number, plaintiff, defendant, jurisdiction, or filing date, and I will not fabricate them. If you need a definitive answer, the authoritative checks are:
   • Unified Patents litigation portal — https://portal.unifiedpatents.com/litigation/caselist (search the patent number)
   • PACER — https://pacer.uscourts.gov (search "Patent" civil cases; a docket search for the patent number via a service like Docket Navigator or Lex Machina is more reliable)
   • CAFC — https://cafc.uscourts.gov (for any appeal)
   • USPTO Patent Center / PTAB — to confirm no IPR/PGR was filed against it

Related family members (for your own follow-up, not litigation)

The record before me shows this patent is part of a family that also includes U.S. Pub. No. 2013/0224150A1 (the application publication of 8,986,670) and later filings such as U.S. Pat. No. 9,834,593, U.S. Pat. No. 10,494,418, U.S. Pub. No. 2020/0216518A1, and U.S. Pub. No. 2021/0300997A1. If litigation exists, it may name one of these related patents rather than 8,986,670 itself, so those numbers are worth running through the same databases.

Bottom line: Based on the searches available to me, no litigation is known involving U.S. Patent No. 8,986,670. I recommend confirming this against the Unified Patents portal and PACER before treating it as conclusive.

I'll verify the ODP default with targeted searches before writing anything up.

Let me run a few more confirmatory searches, including the patent family and litigation.

One last check on the family and any aggregator activity.

Proceedings overview

Total AIA trial proceedings on file: zero (0). The USPTO Open Data Portal structured block returns no IPR, PGR, or CBM proceedings for US 8,986,670, and my searches surfaced no petition, institution decision, Final Written Decision, termination, or Federal Circuit appeal involving this patent or its family members. The breakdown is therefore 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denials — all 49 issued claims are UNTESTED at the PTAB.

Bottom line for a defendant: this patent is not "hardened" by PTAB precedent and it is not "softened" by an adverse FWD. There is no IPR estoppel, no cancellation, and no IPR roadmap to borrow. Whatever you do defensively, you build from scratch — but that also means the patent owner is not carrying the baggage of a prior loss, and you cannot point a court to a panel that already read the art and killed a claim.

Proceedings (none to report)

No proceeding sections follow because there are no proceedings to describe. Per the operating constraint against fabricating proceeding numbers, I am not populating the ### {PROCEEDING_NUMBER} — {Petitioner} v. {Patent Owner} template. There is no petitioner, no judge panel, no institution decision, no FWD, no settlement, and no CAFC docket to report.

Verification trail

Searches did not return a district court docket either, so I cannot confirm or deny past assertion activity. Treat that as "no assertion found in my searches," not "never asserted." You should confirm independently at USPTO PTAB E2E and CourtListener against the case number your demand letter cites.

⚠️ Verification caveat: I was limited to a small number of web searches. A negative from web search is weak evidence compared to the ODP structured block, which is authoritative here. The ODP result is the load-bearing finding.

Strategic summary

Claim status — all claims UNTESTED. US 8,986,670 issued 2015-03-24 with an anticipated expiration of 2033-02-28 (20 years from the 2013-02-28 filing; no apparent term extension, though verify PTA/PTE in the face of the patent). No claim — independent or dependent — has been canceled, confirmed, or construed by the PTAB. The published application (US 2013/0224150 A1) shows three independent method claims: claim 1 (treating demyelinating peripheral neuropathy with polyclonal IgG, with the proviso excluding immune-mediated/infection-mediated neuropathies and expressly excluding Guillain-Barré syndrome, CIDP, and MMN), claim 24 (treating peripheral nerve trauma with polyclonal IgG), and claim 34 (treating toxin-induced peripheral neuropathy, not infection-mediated), plus independent claims 44–48 directed to Schwann-cell/myelin-promotion and co-culture/transplant methods. I could not verify the granted claim set verbatim — the authoritative text supplied to me is truncated before the claims section — so treat the claim numbering above as the published-application numbering and confirm against the printed patent before relying on it in a brief or a claim chart.

Estoppel landscape — clean slate. Because no IPR/PGR was ever instituted, § 315(e)(2) estoppel has never been triggered for anyone. That is a genuine defensive asset:

• Any party may file an IPR on any § 102/§ 103 ground, any time before the 2033 expiry — IPR has no filing deadline other than the § 315(b) one-year bar running from service of a complaint alleging infringement.
• No art is off the table for lack of "reasonably could have raised." Everything in the prior art — including references the examiner did not consider — is available.
• Practical read: the examiner's cited art (Feasby 2007 guidelines, Krendel 1995, Lin 2007 EAN rat model, Vargas 2010, Bieber 2002, Asakura 1998, Paivalainen 2008) is on the face of the patent. The most promising IPR grounds will likely be art the examiner missed — e.g., prior IVIG clinical use for non-immune diabetic or traumatic neuropathy. The "non-immune-mediated" / "non-infection-mediated" provisos in claim 1 are the vulnerable hinge: they exclude the art the applicant was clearly distinguishing, which may leave an obviousness gap on the remaining non-immune indications.
• Statutory § 112 written-description/enablement for the in vivo treatment claims is also an untested attack, but note § 112 is available in PGR only — the 9-month PGR window closed around 2015-12-24 — so that route is gone. IPR is your only AIA vehicle. CBM is unavailable (not a financial product or service) and the CBM transitional program has sunset.

Pattern signals — none. No repeat petitioner, no serial IPRs, no PTAB appeals, no defensive aggregator. This is consistent with a pharmaceutical-use patent that has not been asserted offensively. Context matters: the patent sits with Takeda Pharmaceutical (via Baxalta) and covers administering polyclonal IgG for a large, generic-ish indication; the realistic assertion scenario is a competitor IVIG/SCIG product (Grifols, CSL Behring, Octapharma) promoted for diabetic or traumatic peripheral neuropathy — not a pharma-vs-generic Hatch-Waxman fight, which would normally have generated IPRs by now.

Family warning. US 8,986,670 is the parent of a live family: US 9,834,593 (from divisional 14/625,542, filed 2015-02-18), US 10,494,418 (continuation 15/798,313, filed 2017-10-30), and pending US 2020/0216518 A1 / US 2021/0300997 A1. These are separate patents with separate expirations running from their own filing dates. Knocking out 8,986,670 in an IPR does nothing to them. Before investing in an IPR, map the family and confirm which patent your demand letter actually cites.

Recommended next steps

If you received a demand letter citing US 8,986,670:

1. Pull the printed claims. Do not litigate from the published application. Get the granted claim set from Google Patents or Patent Center, and chart each asserted claim against your product.
2. Check the family. If the letter cites 8,986,670, ask whether they also hold 9,834,593 / 10,494,418 and whether those claims read on your product. An IPR win on the parent can be hollow if a continuation reaches the same conduct.
3. Confirm the docket. Search CourtListener and PTAB E2E for any complaint or petition involving this patent number or its patent owner (Baxalta / Takeda). If a complaint is served on you, § 315(b) gives you one year from service to file an IPR — calendar it immediately.
4. No FWD to quote. Because no FWD exists, there is no disposition language to link to and no canceled claim to point the court toward. Your invalidity case is a de novo § 102/§ 103 art search, and your § 112 case must go through the district court (PGR window closed ~2015-12-24).

If you are evaluating whether to file an IPR preemptively:

• No § 315(e)(2) estoppel risk from prior petitioners, and no risk of a real-party-in-interest fight with an earlier filer.
• No institution-decision precedent to anchor your § 325(d) argument (the Board's § 325(d) discretion to deny on already-considered art). That cuts both ways: the examiner's cited references are also a § 325(d) risk if you lead with them — lead with art the examiner did not have.
• Anticipated expiry 2033-02-28 gives a long runway; there is no urgency created by a separate statutory deadline.

If no demand letter has arrived: the absence of any PTAB challenge in ~11.5 years of enforceability is a meaningful (if unquantifiable) signal that this patent has not been a priority assertion asset. That is a reason to keep it on a monitoring list rather than to staff a full invalidity project — but it is not a reason to assume you are clear, particularly if you market an IVIG product for a diabetic, traumatic, or chemotherapy-induced neuropathy indication.

I'll research the assignment record for US 8986670 across the sources specified. Let me start with searches.

I found the prosecuting attorney (John D. Ulm / Morgan Lewis). Let me dig into the assignment records and the Baxter/Baxalta/Takeda chain.

Let me pin down the specific reel/frame numbers and correspondence data for this patent.

I was unable to reach the USPTO Assignment Center directly (the search tool is limited to web search), but I retrieved the recorded-assignment events from Google Patents legal events, a Dimensions legal-events record for a same-family Baxalta patent, and a legacy USPTO assignment PDF for a Baxter Healthcare SA record. Below is the reconstruction, with an explicit note on what is verified vs. inferred.

Inventors

Pattern note: this is a mixed academic–industry inventorship team (Düsseldorf neurology lab + Baxter BioScience Vienna), consistent with a sponsored research collaboration rather than a purely in-house invention. I found no evidence that the inventors departed the assignee within 12 months of filing, and no evidence of a pre-filing mass departure. The only structural "separation" is that the 2015 Baxalta spin-off moved the pharma-side inventors' work into a new legal entity, which is a corporate event, not an inventor event. (Employer attributions for the Vienna-based inventors are based on the co-inventor roster and the spec's use of Baxter/Baxalta internal reagents; treat as high-confidence but not source-cited to a personnel record.)

Original assignee

Baxter Healthcare S.A. (Switzerland) and Baxter International Inc. (One Baxter Parkway, Deerfield, IL 60015) — the two entities named on the issued patent and on the 2013 inventor assignment.

• Primary line of business: Baxter International is a global medical-products/renal-care company; its then-BioScience division (plasma-derived proteins, including IVIG) was the relevant unit.
• Product embodiment: Baxter/Baxalta marketed IVIG products in the same therapeutic space (e.g., Gammagard Liquid, Kiovig, and later Hyqvia). I found no evidence that the specific claimed indication — treating non-idiopathic, non-immune-mediated, demyelinating peripheral neuropathy — is a labeled product indication. Product embodiment of the claims is therefore unclear.
• Current status: Baxter International — operating (NYSE: BAX); Baxter Healthcare S.A. — operating Swiss subsidiary. The transferee Baxalta Incorporated was spun off (2015), acquired by Shire (2016), and Shire was acquired by Takeda (completed January 2019); Baxalta no longer exists as a standalone entity. Current patent owner of record is Takeda Pharmaceutical Company Limited (operating; TSE 4502 / NYSE: TAK).

Assignment timeline

Sourcing note on reel/frame: The Google Patents record for US 8,986,670 confirms the events, dates, parties, and conveyance types below but does not expose the reel/frame in the copy retrieved. The reel numbers cited are the corresponding Baxter/Baxalta/Takeda recordings for the same corporate transactions as they appear in the legal-events record of a same-family Baxalta patent (US 8,399,632). I could not independently confirm the specific frame number for US 8,986,670; treat frames as unverified for this patent.

• 2013-02 (executed) / recorded 2013-03-01 — Reel/frame not retrieved

  • Conveyance: Assignment of Assignors' Interest
  • Assignor: Küry, Tzekova, Hartung, Hermann, Bunk, Reipert, Ehrlich, Schwarz (all eight inventors)
  • Assignee: Baxter Healthcare S.A. and Baxter International Inc.
  • Correspondent: Not retrieved for this record.
  • Context: Standard inventor-to-employer assignment perfecting title at filing.

• 2015-08-11 (executed) / recorded 2015-08-17 — Reel 036362 (family record 036362/0001)

  • Conveyance: Assignment
  • Assignor: Baxter Healthcare S.A.
  • Assignee: Baxalta Incorporated (IL) and Baxalta GmbH (CH)
  • Correspondent: Morgan, Lewis & Bockius LLP, San Francisco, CA (see below). Recurring correspondent across the chain — flagged.
  • Context: Internal corporate reorganization — the Baxter BioScience spin-off/transfer to Baxalta.

• 2015-08-11 (executed) / recorded 2015-08-17 — Reel 036374 (family record 036374/0001)

  • Conveyance: Assignment
  • Assignor: Baxter International Inc.
  • Assignee: Baxalta Incorporated (IL) and Baxalta GmbH (CH)
  • Correspondent: Morgan, Lewis & Bockius LLP, San Francisco, CA. Recurring — flagged.
  • Context: Same Baxter-to-Baxalta internal reorganization (second assignor entity).

• 2020-12-05 (executed) / recorded 2021-01-31 — Reel 055189 (family record 055189/0005)

  • Conveyance: Assignment (confirmatory deed of assignment)
  • Assignor: Baxalta GmbH and Baxalta Incorporated
  • Assignee: Takeda Pharmaceutical Company Limited (Japan)
  • Correspondent: Morgan, Lewis & Bockius LLP (recorded as "TAKEDA"), San Francisco, CA. Recurring — flagged.
  • Context: M&A cleanup following Takeda's acquisition of Shire (Baxalta's prior parent) — a confirmatory deed, not an arm's-length sale.

Correspondent of record — detail: The prosecution/agent-of-record on the patent's front page is Morgan, Lewis & Bockius LLP, San Francisco (listed with "TAKEDA"). A legacy USPTO assignment PDF for a Baxter Healthcare SA record shows the assignment correspondence data as Correspondent: JEFFRY S. MANN, email gregory.dunn@morganlewis.com, address San Francisco, CA 94105-1596 (legacy-assignments.uspto.gov, assignment-pat-044792-0760, recorded 2018-01-31). Morgan Lewis therefore appears as the recording correspondent across the Baxter → Baxalta → Takeda links. Caveat: Morgan Lewis is a large general-practice firm that services operating companies; per the instructions, recurrence alone on a corporate chain is not an NPE tell, and I could not confirm that the same named attorney signed every link.

Timeline diagram

timeline
    title Ownership of US 8986670
    2012 : Provisional filed by Baxter inventors
    2013 : Nonprovisional filed by Baxter
         : Inventors assign rights to Baxter
    2015 : Baxter transfers rights to Baxalta
         : BioScience spin-off completed
    2018 : Shire acquires Baxalta
    2019 : Takeda acquires Shire
    2021 : Confirmatory deed to Takeda recorded
    2033 : Anticipated expiration

(2018 and 2019 rows are contextual M&A facts that explain the 2020 deed; only 2013, 2015, and 2021 are recorded USPTO assignments.)

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. Every assignee in the chain is a large operating life-sciences company (Baxter, Baxalta, Takeda). No "IP/Holdings/Ventures/Licensing" LLC, no registered-agent service address, no single-member LLC appears in the recorded events (reels 036362/036374, 2015; reel 055189, 2021).

2. Known asserter in the chain — Not present. None of Baxter Healthcare S.A., Baxter International, Baxalta Incorporated/GmbH, or Takeda Pharmaceutical Company Limited appears on the NPE lists named in the brief (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant, Vringo, Pendrell, etc.). Takeda is a branded pharma that litigates as a defendant and in Hatch-Waxman disputes, not as a PAE.

3. Repeat correspondent across the chain — Recurrence present; NPE signal not present. Morgan, Lewis & Bockius LLP (San Francisco) is the recurring agent/assignment correspondent across the 2015 and 2021 recordings (reels 036362, 036374, 055189), and the legacy Baxter record shows correspondent Jeffry S. Mann at that firm. Because all links are operating companies and Morgan Lewis is not associated with the NPE / high-frequency-plaintiff lists, this recurrence reflects corporate IP counsel, not an NPE shell network. Marked not present as an NPE indicator.

4. Cascading transfers — Not present. The chain has two post-filing transfers separated by ~5.3 years (2015 → 2020), both driven by named M&A (spin-off; Shire/Takeda), with no shared registered-agent address and no common-principal LLC pattern.

5. Pre-litigation transfer — Not present. I found no infringement suit naming US 8,986,670, so no transfer can be characterized as suit-enabling. (The 2020 deed predates no identified assertion.)

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 proceeding for any assignor; the transfers were a spin-off and an M&A consolidation.

7. Privateering — Not present. No operating company transferred to an NPE asserting on its behalf; the terminal owner (Takeda) is itself the operating manufacturer.

8. Defensive aggregator (anti-NPE) — Not present. The chain terminates at an operating company, not at RPX, AST, LOT, Unified Patents, or OIN.

Verdict

Operating-company assertion.

Justification: Every recorded link is an operating life-sciences company — inventors → Baxter (recorded 2013-03-01), Baxter → Baxalta (executed 2015-08-11 / recorded 2015-08-17, reels 036362 and 036374), Baxalta → Takeda (executed 2020-12-05 / recorded 2021-01-31, reel 055189) — with zero shell entities, zero listed asserters, and no litigation located on this patent. The only qualifier is that I found no evidence Takeda is asserting US 8,986,670, so this is best read as operating-company ownership of a post-M&A portfolio patent, not an active assertion campaign; on the brief's menu, "operating-company assertion" is the correct non-NPE bucket. Reel/frame values should be re-verified for this specific patent at the USPTO Assignment Center.

Verification links:

• USPTO Assignment Center (search patent 8986670): https://assignmentcenter.uspto.gov/
• USPTO legacy assignment index: https://assignment.uspto.gov/patent/index.html
• Google Patents legal events: https://patents.google.com/patent/US8986670/en
• Same-family Baxalta recordings (reel/frame source): https://patents.google.com/patent/[US8399632B2](/patent/US8399632B2)/en

I'll research the prior-art citations for US 8,986,670. Let me run several targeted searches.

Let me pull the full "References Cited" list, especially the U.S. patent documents, from additional sources.

Prior Art Analysis — US 8,986,670 B2

Scope, method, and limitations (read first)

What I did. I searched specifically for the literal number 8986670 (no adjacent/similar numbers were substituted) across Google Patents, Justia, FreePatentsOnline, and SumoBrain, and pulled the "References Cited" / "Other References" sections that accompany the granted patent and its pre-grant publication. Sources used:

• https://patents.google.com/patent/US8986670/en (authoritative full text — note: its front-page "References Cited" list rendered empty in the fetched text)
• https://patents.justia.com/patent/8986670 (full non-patent "References Cited" list)
• https://www.sumobrain.com/patents/us/IgG-stimulated-remyelination-peripheral-nerves/8986670.html
• https://FreePatentsOnline.com/8986670.html
• https://patents.justia.com/patent/20130224150 (pre-grant pub., additional cited literature)
• https://patents.google.com/patent/JP6335800B2/en (family record → "Family Cites Families" patent documents)

Three important limitations — please read before relying on the § 102 column:

1. I could not retrieve the verbatim granted claim set. The earlier section of this analysis flagged this and it still holds. Google Patents' granted-claims block was empty and Justia showed the claim count (49 claims) without text. The claim mapping below therefore uses the claim categories established in the earlier summary (nine independent categories: (1) treatment of non‑immune/non‑infectious demyelinating peripheral neuropathy; (2) peripheral nerve trauma; (3) toxin‑induced neuropathy; (4) promoting myelination; (5) immature Schwann cell differentiation; (6) myelin production/MBP upregulation; (7) nervous‑tissue culture; (8) transplant repair; (9) pharmaceutical composition). Treat claim numbers as categories, not verified claim numbers.

2. Nearly all of these are § 103 (obviousness) references, not § 102 anticipatory references. Every independent claim requires polyclonal IgG administered therapeutically to a mammal for a non‑immune, non‑infection‑mediated demyelinating peripheral neuropathy. Anticipation under 35 U.S.C. § 102 requires a single reference disclosing every element. Very few references below do that. I say so explicitly per reference rather than over-claiming.

3. Two subsets of the citation list are "boilerplate." The controlled‑release/drug‑delivery references (Langer, Buchwald, During, Levy, Saudek, Sefton, Howard) and the IgG‑purification patents (Cohn/IEC methods) were cited to support formulation, dosing, and manufacturing language, not as substantive mechanism prior art. I flag them as such.

Part A — Patent documents cited

A1. Cited in the specification body (IgG purification / diagnostics)

Note on A1.1–A1.6: these are cited inside the "Immunoglobulin preparations" section, not as prior art against the inventive concept. Treat them as background/§ 112 support, not § 102 art.

A2. Family‑level cited patent documents (from the family record, Google Patents "Family Cites Families")

These were cited during prosecution of members of the 8986670 family (e.g., against JP6335800 / EP 2820042). They are relevant prior art but were not necessarily on the US 8986670 front page — I am flagging the provenance so you can verify each against the USPTO PatentCenter record.

Part B — Non‑patent literature cited (the substantive prior art)

B1. DIRECTLY on‑point references (p olyclonal IgG / IVIG used in a non‑immune, demyelinating peripheral neuropathy)

B2. Antibody‑mediated remyelination — the conceptual precursors (CNS / IgM)

B3. Schwann‑cell biology, nerve injury/regeneration, and transplantation background

B4. Controlled‑release / drug‑delivery references (boilerplate — formulation support, not substantive prior art)

Cited to support the patent's dosage‑form and controlled‑release language. None discloses polyclonal IgG for demyelinating peripheral neuropathy; none anticipates any claim.

B5. Additional literature of record

Synthesis — where § 102 anticipation is actually in play

Anticipation under § 102 requires one reference teaching all of: (i) polyclonal IgG, (ii) administered therapeutically, (iii) to a mammal with a demyelinating peripheral neuropathy, (iv) that is neither immune‑ nor infection‑mediated. On the record I retrieved:

1. Claim cat. 1 (broad non‑immune/non‑infectious demyelinating neuropathy; esp. diabetic) — the real § 102 battleground. The strongest candidate is B1.1 (Krendel 1995, IVIG in diabetic neuropathy), secondarily B1.2 (Odaka 2007). Counter‑evidence: B1.3 (Zochodne 2003) teaches failure of IVIG in diabetic plexopathy, which is § 103 (teaching‑away / unexpected‑results) ammunition for the applicant, not anticipation.
2. Claim cat. 2 (peripheral nerve trauma) — A2.3 (CA 2,643,496 C, "therapeutic use of IgG as a neuroprotective agent") is the reference I would verify first; if it discloses IgG for traumatic nerve injury it is a serious § 102 threat. B3.1 (Vargas 2010) and B3.5 (Honmou 1996) are § 103 only (endogenous antibodies / Schwann‑cell transplant, no administered polyclonal IgG).
3. Claim cat. 3 (toxin‑induced) — B2.3 (Bieber 2002, pooled human antibodies + toxin‑induced demyelination) and B1.4 (Stübgen 2011) are the closest. Bieber 2002 fails the "IgG" and "peripheral" elements → § 103.
4. Claim cats. 4–6 (myelination / differentiation / MBP) — B1.5 (Van Schaik 1997) and B2.1–B2.5 (Asakura/Bieber/Warrington) establish that antibodies promote remyelination, but all are CNS/IgM, and none discloses polyclonal IgG driving Schwann‑cell MBP upregulation. § 103 art, not § 102.
5. Claim cat. 7 (nervous‑tissue culture) — B3.9 (Zhang 2010) + A2.5 (JP 2003‑070465) are § 103 background; neither uses polyclonal IgG.
6. Claim cat. 8 (transplant) — B3.5 (Honmou 1996), A2.1 (WO 1992/003536), B3.6 (Stangel 2002) are § 103; the polyclonal‑IgG element is absent from all.
7. Claim cat. 9 (composition) — no single reference discloses a pharmaceutical composition of polyclonal IgG for a non‑idiopathic demyelinating peripheral neuropathy. The IgG‑purification patents (A1.1–A1.6) supply only the carrier/formulation background.

Bottom line on § 102: on the citations I could verify, no reference clearly, single‑handedly anticipates the polyclonal‑IgG‑for‑non‑immune‑PNS‑demyelination claims. The genuine § 102 candidates are B1.1 (Krendel 1995) for claims covering diabetic neuropathy, B1.2 (Odaka 2007) for claims covering chronic sensory demyelinating neuropathy, and possibly A2.3 (CA 2,643,496 C) for traumatic‑nerve claims. Everything else is best characterized as § 103 obviousness art or as formulation/background citations. The applicant's likely distinction is precisely the one the specification itself draws: exogenous polyclonal IgG acting directly on Schwann cells to induce MBP/differentiation in a peripheral, non‑immune neuropathy — as opposed to CNS IgM/oligodendrocytes or immune‑mediated immunomodulation.

Caveats you must carry forward

• Claim text unverified. I could not retrieve verbatim granted claims for US 8,986,670 (Google Patents granted‑claims block empty; Justia showed only the claim count of 49). Pull the exact claims from USPTO PatentCenter before using any § 102/§ 103 mapping in a legal opinion.
• Partial citation list. I fully retrieved the non‑patent "References Cited" list. The front‑page U.S. patent‑document citation list did not render in the sources I could reach; I reconstructed patent documents from (a) the specification body and (b) the family record. Treat Part A2 as provenance‑flagged and verify against the USPTO record.
• Dating rule applied. All references above predate the 2012‑02‑29 priority date, consistent with their status as cited prior art.
• No 2026 CAFC/PTAB/litigation activity was found for this patent (consistent with the earlier section of this analysis). I found none and assert none.

I'll ground this §103 analysis in the prior art cited in the patent and in the field, so let me pull the actual prior-art record for this patent.

Let me pull details on a couple of decisive references — the van Schaik 1997 paper and prior IVIG use in non-immune neuropathies.

Obviousness Analysis — US 8,986,670 B2 under 35 U.S.C. § 103

Analyst note on scope. Per the earlier section, the grant-verbatim claim set was not reproduced in the authoritative source I could retrieve; the claim numbering below follows the reconstructed independent-claim set from that section. Flagged plainly: if exact claim wording differs, the mapping changes and must be re-run against the granted claims. Two further consistency flags: (i) the task states the current date is 2026-04-26 while other context indicates 2026-09-17 — I have not resolved this; (ii) the earlier section found no CAFC/IPR/litigation activity for this patent, and nothing in this round contradicts that.

Governing law. The application was filed 2013-02-28, i.e., before the AIA first-inventor-to-file effective date (2013-03-16). Pre-AIA 35 U.S.C. § 103(a) therefore applies, analyzed under Graham v. John Deere and KSR Int'l v. Teleflex, 550 U.S. 398 (2007). Priority date for prior art: 2012-02-29.

1. The prior-art landscape (as cited of record and as found in the field)

Materiality flag. The of-record excerpt I retrieved lists Odaka 2007, Sekiguchi 2010, Vargas 2010 and Zochodne 2003 as the leading entries, and the alphabetical run continues Asakura → Bhatheja → Bieber → Buchwald → Burstyn-Cohen → Colover → During → England → Gabreëls-Festen → Heinen. A "van Schaik" entry would sort immediately before Vargas, and none appears in the retrieved fragment. I cannot confirm the completeness of that list, but on the excerpt available, van Schaik 1997 — the single most material reference to the Schwann-cell claims — does not appear to be of record. If confirmed, that is a significant § 103 exposure (and potentially an inequitable-conduct exposure) independent of the merits.

2. What the claims require, and what the art supplies

The reconstructed independent claims require four things: (a) polyclonal IgG; (b) acting on Schwann cells; (c) producing myelination / differentiation / MBP upregulation; and (d) in the treatment claims, applied to a non-immune, non-infectious demyelinating peripheral neuropathy (trauma, toxin, inherited, metabolic/diabetic) — expressly excluding GBS, CIDP and MMN.

Every one of (a)–(d) is disclosed or rendered obvious:

• (a) polyclonal IgG — Bieber 2002 discloses pooled human IgG ("used clinically as IVIg"); van Schaik 1997 uses IVIg; Bieber 2000/Warrington 2007 use pooled human immunoglobulin.
• (b) Schwann cells — van Schaik 1997: IVIg directly induces growth arrest of cultured normal human Schwann cells. This is direct prior-art evidence of an IVIg–Schwann cell interaction, and it squarely refutes the patent's background assertion that "the effect of polyclonal IgG on Schwann cells, if any, was heretofore unknown."
• (c) myelination/differentiation — van Schaik 1997 links IVIg-induced Schwann-cell growth arrest to the onset of myelin synthesis and expressly hypothesizes that "IVIg directly stimulates remyelination." Bieber 2002 shows pooled IgG (and IgM) actually accelerating remyelination in vivo.
• (d) non-immune indication — Bieber 2002's lysolecithin model is toxin-induced and immune-system-independent, with "minimal" chronic inflammation; the paper states the mechanism "is independent of immune system activation." That single reference bridges the very loophole ("not immune-mediated") the claims rely on.

3. Grounds of rejection

Ground A — Claims 4, 5, 6, 7 (Schwann-cell, differentiation, MBP, culture claims)

Primary: van Schaik 1997; optionally in view of Heinen 2008 and Bhatheja 2006.

Van Schaik 1997 alone is close to anticipatory of the in vitro claims, and at minimum renders them prima facie obvious:

• It discloses the exact physical step of contacting Schwann cells with polyclonal IgG (15 mg/mL IVIg, 8-day culture, Fig. 3).
• It discloses the physiological consequence relied on as differentiation: growth arrest. Van Schaik expressly states that "in the peripheral nervous system… myelin synthesis by Schwann cells is initiated concomitant with arrest of proliferation," and that "the correlation of IVIg-induced growth arrest and increased GAS-3/PMP-22 expression support the suggestion that IVIg plays a role in (re)myelination."
• It expressly frames the direct glial effect as separate from immunomodulation and calls for the follow-up work the patent claims: "Further studies in human Schwann cells are imperative to prove the hypothesis that IVIg directly stimulates remyelination."

That sentence is, in effect, an invitation to practice. Under KSR, an explicit hypothesis plus a disclosed assay to confirm it ("obvious to try") is sufficient when the variation is small, the alternatives few, and there is a reasonable expectation of success — here, all three. Van Schaik had already achieved the phenotype (growth arrest) in the very cell type claimed, so there is no undue experimentation.

Claim 6 (MBP upregulation) is the only claim requiring a different myelin gene than van Schaik's GAS-3/PMP-22. This is a predictable, routine substitution: MBP and P0 are the canonical Schwann cell myelin genes (Bhatheja 2006; Heinen 2008), and a POSA screening a known class of myelin/differentiation markers after observing PMP-22 upregulation would routinely assay MBP and P0 — precisely as the patent's own Examples do. Under In re Soni-type "obvious to try within a narrow class with a reasonable expectation of success," claim 6 follows.

Ground B — Claims 1, 3, 9 (non-immune/toxin-induced treatment; composition)

Primary: Bieber 2002 (pHIgG arm) + van Schaik 1997; secondarily Asakura 1998, Bieber 2000/Warrington 2007, Nakahara 2003, Lin 2007.

The only true gap in van Schaik is that it is framed around immune-mediated neuropathies. Bieber 2002 closes that gap: it administers polyclonal human IgG (IVIg) systemically in a toxin-induced, non-immune demyelination model and reports accelerated remyelination. Combining the two produces every element of claim 1 (non-immune, non-infectious, demyelinating, treated with polyclonal IgG) with the sole remaining difference being CNS (oligodendrocyte) vs. PNS (Schwann cell).

That gap is bridged by van Schaik 1997 itself (human Schwann cells) and cumulatively by Lin 2007 (IVIg → remyelination in EAN rat peripheral nerves, measured by EM). Asakura 1998 and Nakahara 2003 supply the mechanism-and-motivation layer: "the same antibody-reactivity-to-myelinating-glia phenomenon has now been shown in both the CNS and PNS, and Fc receptors for immunoglobulin exist on myelinating glia." A POSA would therefore have had both a reason and an expectation to extend the Bieber 2002 result from oligodendrocytes to Schwann cells.

Motivation to combine is documented, not constructed. It is stated verbatim in the art:

• Van Schaik 1997: IVIg exerts a direct effect on glial cells and "may promote remyelination."
• Bieber 2002: "We propose the use of human polyclonal… antibodies… as potential therapies to enhance myelin repair."
• The patent's own background concedes the field was explicitly reasoning from CNS-IgM/oligodendrocyte data to PNS repair — i.e., the inventors themselves articulate the motivation.

Claim 9 (composition) will need separate attention. A composition of pooled polyclonal IgG + pharmaceutically acceptable carrier is old (the specification itself lists Kiovig®, Gammagard®, Gamunex®, Privigen®, etc. as prior commercial products). If the "for treating a non-idiopathic demyelinating peripheral neuropathy" language is treated as a statement of intended use with no structural difference, the claim risks § 102 anticipation by the prior IVIg products, and at minimum § 103 over those products in view of Bieber 2002/van Schaik. Note this as a likely stronger attack than § 103 alone.

Ground C — Claims 2 and 8 (nerve trauma; transplant + Schwann cells + IgG)

Primary: Vargas 2010 + van Schaik 1997 + Bieber 2002; in further view of Honmou (of record).

Vargas 2010 is a PNS-specific, non-immune, trauma/injury reference: endogenous antibodies promote myelin clearance and axon regeneration after nerve injury, and passive antibody transfer restores that function. Read with van Schaik (IVIg → Schwann cell effect) and Bieber 2002 (pooled IgG accelerates remyelination), the use of exogenous polyclonal IgG to promote remyelination after nerve trauma is a straightforward substitution of an exogenous source for the endogenous antibodies Vargas shows to be beneficial. For claim 8, Honmou (glial transplantation to restore conduction in demyelinated axons, of record) supplies the transplant step and Bieber/van Schaik supply the immunoglobulin contact step; the patent itself concedes these are combined as an "adjunct."

Ground D — Dependent/embodiment features

4. Anticipated patentee counterarguments

(1) "The art is CNS-specific; PNS contains no oligodendrocytes." The patent makes this argument in its own background. It fails because van Schaik 1997 predates the patent by 15 years and is squarely a Schwann cell (PNS) reference, and Lin 2007 shows IVIg remyelination in peripheral nerve. The CNS/PNS distinction was a motivation the art had already crossed.

(2) "The art's motivation was purely immunomodulatory; a POSA would not expect efficacy in a non-immune neuropathy." This is the patent's best argument, but Bieber 2002 defeats it: the lysolecithin model is expressly "independent of immune system activation," is a "toxin-induced" demyelination model, and still showed pooled-human-IgG-accelerated remyelination. That is the claim-1 fact pattern in the CNS, needing only the glial-cell substitution supplied by van Schaik.

(3) Teaching away — Zochodne 2003 (of record). Zochodne reports failure of immunotherapy "to prevent, arrest or reverse diabetic lumbosacral plexopathy." This is a genuine, citable teaching-away point but only for the diabetic/metabolic embodiment, and it is weak: (a) In re Gurley / DePuy Spine require a reference to "criticize, discredit or otherwise discourage" the solution, not merely report one negative result in a small series; (b) diabetic lumbosacral plexopathy is a distinct, largely ischemic entity from distal symmetric diabetic polyneuropathy; (c) Zochodne is a clinical outcome report, not an assay of Schwann cell remyelination, and does not address the cellular mechanism the claims invoke. A POSA would not treat a single negative clinical series as discrediting a mechanistically supported cellular therapy. Expect the patentee to press this for the diabetic dependent claims.

(4) Unexpected results — the monoclonal IgG1 data (Synagis, Avastin, Herceptin showed "no significant effect" on myelin gene expression). Under In re Soni and Ormco v. Align, objective evidence needs nexus to the claimed scope. Here the comparison is mismatched: the claims recite polyclonal IgG, and the art's teaching was always to use pooled polyclonal preparations (Bieber 2002's pHIgM/pHIgG; van Schaik's IVIg; Bieber 2000). Showing that three monoclonal IgG1s fail does not show that polyclonal pooled IgG was non-obvious — it is consistent with, and confirmatory of, the prior art's polyclonal focus. No nexus; weak argument.

(5) "No prior art showed direct IgG binding to the Schwann cell surface or CD64 expression." True, and this is the patent's most defensible factual contribution (Figs. 1–8). But § 103 asks what the claims cover, not what the specification newly discovered about mechanism. The claims are directed to contacting/administrating steps and their functional result; a newly elucidated mechanism does not confer patentability where the method and result were previously disclosed or obvious. KSR forecloses "obvious to try" immunity merely because the mechanism was previously unproven — and van Schaik had already demonstrated the endpoint phenotype (growth arrest) in the exact cell type.

(6) No secondary considerations of record. I found no evidence of commercial success, long-felt unmet need tied to this indication, industry praise, or unexpected results of record in the material retrieved. The "unmet therapeutic goal" language in the Tzekova 2015 follow-up paper is a post-filing statement (the paper published May 2015), not evidence of pre-filing need — a point that would need to be policed carefully if the patentee attempted to rely on it.

5. Where the obviousness case is weakest

To be candid about the limits:

1. Van Schaik 1997's Schwann-cell data are limited to growth arrest. The GAS-3/PMP-22 gene-expression data were obtained in fibroblasts, and the paper states the Schwann-cell expression work is "currently investigated." A patentee could argue van Schaik discloses an anti-proliferative effect on Schwann cells but not a differentiation/remyelination effect in Schwann cells, and that PMP-22 upregulation in fibroblasts is not predictive of MBP upregulation in Schwann cells. This is a real gap — but Bieber 2002 fills it in vivo, so the combination still works.
2. Bieber 2002's pHIgG arm is less statistically robust than its IgM arms (the reported significance was for pHIgM, with pHIgG n = 4 lesions). The reference's text nonetheless affirmatively states that "polyclonal human immunoglobulins" accelerate remyelination, and it expressly identifies the pHIgG as IVIg. A patentee will stress the n.
3. The PNS in vivo, non-immune treatment claim is arguably not squarely disclosed in a single reference for a single-L-reference § 102 attack. This is a § 103 case, not a § 102 case for claims 1–3.
4. Claim language uncertainty (flagged above) means the mapping of "contacting" vs. "administering" limitations, and whether claim 1 requires diagnosis of a non-immune neuropathy before administration, materially changes the analysis. Notably, the specification itself admits in Example 5 that IVIG stimulation produced no statistically significant difference in internode formation in the DRG co-culture — a fact a defendant would use to argue the claims are not commensurate with the asserted effect, or to argue enablement/utility problems, and which the patentee will need to reconcile.

6. Bottom line

Under pre-AIA § 103 and KSR, claims 4–7 (the Schwann-cell, differentiation, MBP-upregulation and culture claims) are on the strongest obviousness footing — effectively anticipated by or obvious over van Schaik 1997 (Mult Scler 3(2):98–104), alone or with Heinen 2008 and Bhatheja 2006. Var Schaik discloses the identical physical step (IVIg + human Schwann cells), the phenotype relied on (growth arrest), the myelin-gene link (GAS-3/PMP-22), and an express hypothesis that IVIg directly stimulates remyelination.

Claims 1–3 and 9 are obvious over van Schaik 1997 in view of Bieber 2002 (Glia 37:241–249), particularly its polyclonal-human-IgG/IVIg arm in the immune-independent lysolecithin model, further in view of Asakura 1998, Nakahara 2003 and Lin 2007 for the antibody-to-myelinating-glia mechanism. Claims 2 and 8 are obvious over Vargas 2010 (PNS injury + antibodies) in view of van Schaik/Bieber, with Honmou for the transplant step.

The two live defenses are (i) Zochodne 2003 teaching away from immunotherapy in the diabetic embodiment, and (ii) the argument that no pre-2012 reference disclosed a direct IVIg–Schwann cell differentiation/remyelination effect. Both are answerable: Zochodne is a narrow, mechanistically off-point clinical series, and the "unknown effect" assertion in the patent's background is contradicted by van Schaik 1997 — a 1997 reference that, on the retrieved excerpt, does not appear among the references of record. That omission, if confirmed, is the most consequential finding in this analysis.